Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2017 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. Look for statements about deals, contracts, projects, customers, sites, programs being individually bigger, broader, longer than before. Scan transcript for such language. For example, Larry Renfro mentions OptumInsight backlog growth, but that's total backlog, not necessarily unit size. He mentions "West Virginia became the first state to engage Optum to integrate program eligibility across all state sponsored health benefit program" - that's a new type of engagement, not necessarily larger than past. He mentions "multi-year award to manage the technology platform modernization for SSS, Blue Cross Blue Shield Puerto Rico" - not clear if larger. Look for explicit comparisons. For example, "we now manage more than $65 billion in annual billings" - that's scale, not unit size. Check for statements about new customers starting at larger scope. For instance, "The healthcare transformation alliance relationship is off to an excellent start with 10 companies selecting OptumRx" - that's number of customers, not size per customer. Maybe about OptumCare expansion: "we expanded OptumCare primary care driven practices into 10 new major metropolitan areas" - that's geographic expansion, not necessarily larger per deal. Look for "largest" or "biggest" deals. There is mention of DaVita Medical Group acquisition, but that's an acquisition, not a contract. Also Banmedica acquisition. The question is about successive engagements of the same kind - like contracts, orders, projects. The transcript doesn't seem to have management saying that the size of each new deal is larger than previous ones. They talk about growth in backlog, but that could be from more deals, not larger deals. Also, they mention "we expect to add Banmedica in the first quarter 2018" - that's an acquisition, not a contract. No clear statement of escalation in unit size. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.